Department of Chemistry of Biofunctional Molecules

Chemistry of Biofunctional Molecules

Course of Pharmaceutical Sciences

Teaching staffs

Name, Position Email
*convert [a] to @
Tel Fax

Asako Yamayoshi,

Ph. D.

asakoy[a] +81-95-819-2438 +81-95-819-2479

Tsuyoshi Yamamoto,

Ph. D.
Associate Professor


+81-95-819-2479 +81-95-819-2479

Yu Mikame,

Ph. D.
Assistant Professor


+81-95-819-2439 +81-95-819-2479

Research interests

  • Development of nucleic acid drugs for functional regulation of non-coding RNAs
  • Novel drug delivery system using circulating extracellular vehicles
  • Development of novel photodynamic regulation system for regulation of epigenetic gene expression
  • Parmacokinetic manipulation of oligonucleotide drugs using ligand-targeted strategy
  • Genome editing application of nucleic acid chemistry

Selected publications

  • Nakao J, Mikame Y, Eshima H, Yamamoto T, Dohno C, Wada T, Yamayoshi A: Unique crosslinking ppoperties of psoralen-conjugated oligonucleotides developed by novel psoralen N-hydroxysuccinimide esters. ChemBioChem, in press. DOI:10.1002/cbic.202200789
  • Kojima A, Nakao J, Shimada N, Yoshida N, Abe Y, Mikame Y, Yamamoto T, Wada T, Maruyama A, Yamayoshi A: Selective photo-cross-linking detection of methylated cytosine in DNA duplex aided by a cationic comb-type copolymer. ACS Biomater Sci Eng 8: 1799-1805, 2022
  • Wada F, Yamamoto T, Kobayashi T, Tachibana K, Ito KR, Hamasaki M, Kayaba Y, Terada C, Yamayoshi A, Obika S, Harada-Shiba M: Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides. Mol Ther Nucleic Acids 26: 957-969, 2021
  • Terada C, Wada F, Uchida M, Yasutomi Y, Oh K, Kawamoto S, Kayaba Y, Yamayoshi A, Harada-Shiba M, Obika S, Yamamoto T: Programmed instability of ligand conjugation manifold for efficient hepatocyte delivery of therapeutic oligonucleotides. Nucleic Acid Ther 31: 404-416, 2021
  • Yamayoshi A, Oyama S, Kishimoto Y, Konishi R, Yamamoto T, Kobori A, Harada H, Asihara E, Sugiyama H, Murakami A: Development of antibody—oligonucleotide complexes for targeting exosomal microRNA. Pharmaceutics 12: 545, 2020


Please find latest works in their website.